Caris Life Sciences Unveils the Next Evolution of Liquid Biopsy with Enhanced Caris Assure

{
  "signal_id": "cba43f25-ecdc-296d-3485-9fd901bd5ea4",
  "signal_type": "news",
  "signal_subtype": "launches",
  "detected_at": "2026-09-29T10:30:00+00:00",
  "company": {
    "name": "Caris Life Sciences",
    "domain": "carislifesciences.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/caris-life-sciences-unveils-the-next-evolution-of-liquid-biopsy-with-enhanced-caris-assure-302892201.html",
    "title": "Caris Life Sciences Unveils the Next Evolution of Liquid Biopsy with Enhanced Caris Assure",
    "excerpt": "Integrated DNA, RNA and Whole-Blood Analysis Provides Deeper Molecular Insights for Precision Oncology IRVING, Texas , Sept. 29, 2026 /PRNewswire/ -- Caris Life Sciences ® (Caris), a leading AI TechBio company, today unveiled the enhanced Caris Assure®, a new evolution of liquid biopsy. By integrating Whole Exome Sequencing (WES), Whole Transcriptome Sequencing (WTS) and whole-blood analysis (for true CHIP identification) into a single platform, the enhanced Caris Assure assay provides a more complete molecular profile from a single blood draw, delivering deeper insights to help guide precision oncology decisions. Designed to address longstanding limitations of traditional liquid biopsy approaches, enhanced Caris Assure incorporates multiple improvements to its comprehensive DNA and RNA analysis combined with whole-blood testing to help distinguish tumor-derived alterations from clonal hematopoiesis and incidental germline findings. The enhanced version of Caris Assure includes validation that tumor fraction correlates with risk of progression and treatment efficacy in patients who receive repeated testing, and results are categorized into molecular response, intermediate, or molecular progression for patients with multiple tests while on treatment. This additional capability creates the opportunity to use Caris Assure to understand how patients are benefiting from their...",
    "product": "Caris Assure",
    "summary": "Caris Life Sciences has launched an enhanced version of its Caris Assure liquid biopsy platform, which integrates Whole Exome Sequencing, Whole Transcriptome Sequencing, and whole-blood analysis.",
    "location": "Irving, Texas, USA",
    "planning": false,
    "image_url": "https://mmx.prnewswire.com/media/MS863020/Caris-Life-Sciences-Logo.jpg?id=OA2975495&p=facebook",
    "confidence": 0.95,
    "product_data": {
      "name": "Caris Assure",
      "full_text": "enhanced Caris Assure®, a new evolution of liquid biopsy",
      "fuzzy_match": false,
      "release_type": "update"
    },
    "product_tags": [
      "online_technology",
      "general_technology",
      "medical",
      "data",
      "future_tech"
    ],
    "published_at": "2026-09-29T10:30:00Z",
    "location_data": [
      {
        "city": "Irving",
        "state": "Texas",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-09-29",
    "article_sentence": "Caris Life Sciences ® (Caris), a leading AI TechBio company, today unveiled the enhanced Caris Assure®, a new evolution of liquid biopsy."
  }
}

curl https://signals.autobound.ai/v1/signals/cba43f25-ecdc-296d-3485-9fd901bd5ea4 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"carislifesciences.com","limit":20}'